| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 0 | 5,110 | 5,820 | 5,990 | 7,810 |
| Sales Growth | -100.00% | -12.20% | -2.84% | -23.30% | -18.31% |
| Net Income | 1,910 | -14,320 | -8,160 | -20,040 | -8,990 |
| Net Income Growth | +113.34% | -75.49% | +59.28% | -122.91% | +56.34% |
Petros Pharm Inc (PTPI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Petros Pharmaceuticals Inc. is a men's health company. It engages in identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie's disease, hormone health and substance use disorders. Petros Pharmaceuticals Inc., formerly known as Neurotrope Inc., is based in NEW YORK.
Fiscal Year End Date: 12/31